摘要
器官缺血再灌注损伤(IRI)是临床医师面临的重大挑战,然而其机制仍未阐明,且临床治疗效果仍不理想。聚(ADP-核糖)聚合酶1(PARP-1)依赖性细胞死亡(又名Parthanatos)是一种非凋亡性的程序性细胞死亡途径,参与器官IRI的发生发展。同时Parthanatos也是一种多步骤途径,Parthanatos级联中有许多关键分子可作为IRI的干预靶点,包括PARP-1、凋亡诱导因子(AIF)和巨噬细胞迁移诱导因子(MIF)等,这些关键分子参与了IRI所致的DNA损伤、能量耗竭、稳态失衡等。因此,Parthanatos级联中的这些分子信号也将可能是治疗IRI的新靶点。本文综述PARP-1依赖性细胞死亡的机制及分子特征,并阐述其与重要器官IRI的关系,旨在探寻器官IRI机制研究和临床治疗的视野,以期为临床医师及科研工作者提供新思路。
Ischemia reperfusion injury(IRI)of organs is a major challenge for clinicians,but the mechanism is still not elucidated,and the clinical treatment effect is still unsatisfactory.PARP-1-dependent cell death(parthanatos)is a non-apototic programmed cell death pathway involved in the development of the occurrence of IRI of organs.At the same time,parthanatos is also a multi-step pathway.There are many molecules in the parthanatos cascade that can be exploited to create therapeutic interventions for IRI,including PARP1,apoptosis inducing factor(AIF),and macrophage migration inhibitory factor(MIF).These critical molecules are involved in DNA damage,energy depletion and homeostasis imbalance.Therefore,these molecular signals in the parthanatos cascade represent promising therapeutic targets for the treatment of IRI.In the following,we will elaborate on the mechanisms and molecular characteristics of the parthanatos pathway and the relation between parthanatos pathway and IRI of vital organs.It aims to explore the posibility of IRI mechanism research and clinical treatment and to provide new ideas for clinicians and researchers.
作者
王路瑶
唐轶珣
刘景诗
刘际童
Wang Luyao;Tang Yixun;Liu Jingshi;Liu Jitong(Department of Anesthesiology,Hunan Provincial People's Hospital(The First Affiliated Hospital of Hunan Normal University),Changsha 410000,China)
出处
《中国医师杂志》
CAS
2023年第4期626-629,共4页
Journal of Chinese Physician
基金
湖南省自然科学基金面上项目(2020JJ4404)。
